Imperial Brands (IMB/IMBBY) shares fell 8% as currency headwinds, a $200M legal settlement, and market share losses clouded its fiscal 2026 earnings outlook.

Key Highlights

  • Imperial Brands shares fell over 8% on April 14 after a mixed first-half trading update.
  • Foreign exchange translation swung from a 2-2.5% tailwind to a comparable headwind on revenue and earnings per share.
  • A $200 million U.S. legal settlement payment added unforeseeable cost pressure to first-half results.
  • The company flagged modest market share losses across its five largest markets in the first half.
  • Full-year adjusted EPS growth guidance of at least high-single-digit and free cash flow above £2.2 billion were maintained.

Currency Reversal Dominates the Headline Risk

Imperial Brands PLC delivered a first-half trading update on April 14 that fell short of investor expectations across several fronts, triggering one of the sharpest single-day share price declines for the Bristol-based tobacco group since September 2019.

The company is listed on the London Stock Exchange under the ticker IMB and trades in the United States as an American Depositary Receipt on the OTC market under the ticker IMBBY. The ADR has a market capitalisation of approximately $32.47 billion, reflecting Imperial's standing as one of the largest international tobacco groups outside China.

The most consequential element of the update was a material foreign exchange reversal. What had been modelled as a 2 to 2.5% tailwind on both revenue and full-year earnings per share shifted to a headwind of equivalent magnitude. For a company operating across the United States, Europe, the Middle East, and Australia, currency translation risk is a structural variable that management can only partially hedge. Imperial's international exposure creates significant currency risk, as much of its debt is denominated in US dollars, meaning a strengthening US dollar can weigh on the firm's ability to service debt obligations. The scale of this swing was not anticipated by the market, and it constitutes the single largest driver of downward earnings revision pressure from this update.

The shares fell to 2,905 pence intraday on the London exchange, with some estimates placing the decline at over 8% by mid-session. On the US OTC market, IMBBY ADR holders faced equivalent pressure as the move translated across currency and time zones.

Legal Settlement Adds Quantifiable Drag

Compounding the foreign exchange impact was a previously disclosed but now cash-realised legal liability. Imperial paid $200 million to R.J. Reynolds in the first half following an adverse ruling by Delaware's Supreme Court in December 2025. A further $234 million remains payable in roughly equal instalments over three years.

Annual payments of approximately $24 million will flow through cost of goods sold, creating a drag of around 60 basis points on adjusted operating profit. Analysts at Morgan Stanley noted this was not fully reflected in consensus estimates, suggesting further modest downward revisions to full-year earnings per share forecasts are probable.

The settlement underscores a recurring risk for large tobacco groups: legacy litigation in the United States remains a source of unpredictable capital outflows, regardless of operational performance. For US-based IMBBY holders, this liability is denominated in their home currency, making the cash impact more directly visible than it may appear in sterling-reported figures.

Core Trading Performance: Adequate, Not Impressive

Stripping out the currency and legal noise, the underlying trading picture was broadly stable but lacked positive surprise. Group tobacco and next-generation product net revenue is expected to grow at a low-single-digit percentage rate at constant currency in the first half, modestly below the 2.3% consensus estimate. Group adjusted operating profit is anticipated slightly above the prior year period.

The company reaffirmed its full-year guidance: at least high-single-digit adjusted EPS growth, group adjusted operating profit growth of 3 to 5%, and free cash flow exceeding £2.2 billion for fiscal 2026. The guidance maintenance offered some floor to investor sentiment, though the reliance on a stronger second half to deliver these targets introduces execution risk.

Next-Generation Products: Uneven Progress

Imperial's strategic pivot toward smoking alternatives produced an uneven first-half result. Net revenue from next-generation products grew at mid-to-high single digits, falling short of the company's full-year double-digit ambition. Divisional losses ran moderately higher than anticipated.

Performance was geographically split. In the United States, NGP revenue declined due to elevated promotional spending around the Zone nicotine pouch brand. Zone has been rolled out in the US modern oral market, with distribution expanding to more than 70,000 US stores by 2025. Zone held volume share, but the margin cost of that defence was visible. In Europe, results were more constructive, with double-digit NGP revenue growth led by the Pulze 3 heated tobacco device in Italy and Greece.

Market Share and Macro Uncertainty

In what may prove the most structurally significant disclosure, Imperial acknowledged it expects modest market share reductions across its five largest markets, namely the United States, Germany, the United Kingdom, Spain, and Australia, in the first half. In the United States, Imperial sits as the third-largest cigarette manufacturer, a position it consolidated following its acquisition of the Winston and Blu brands. Morningstar The company framed the expected share losses as a deliberate consequence of its shift toward prioritising profitability over volume. Analysts at RBC flagged the expected decline as a source of concern, noting that Imperial's cumulative 48-basis-point market share gain over the preceding five years had been central to its commercial rehabilitation.

On the macroeconomic front, Imperial noted uncertainty stemming from the Middle Eastern conflict, particularly the near closure of the Strait of Hormuz, which has elevated energy and freight costs globally. The company reported no material business impact to date but signalled that second-half trading could be affected. A further update is expected alongside half-year results on May 12.

Morgan Stanley, which maintains an overweight rating on Imperial with a price target of 3,200 pence, noted that the stock trades at approximately 8.8 times 2026 earnings, a roughly 25% valuation discount to British American Tobacco.